Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

The link you posted doesn't quite apply to the current kevetrin trial. In the case of the CTIX kevetrin phase I trial at Dana Farber we have a primary and a seconday objective. Our primary is safety and the secondary is efficacy. When you look at the quote from your link our phase I is more like a phase I/II. The way the CTIX phase I is designed will speed the entire process up quite a bit. So, when this latest CTIX pr says The information that we have received at this early stage of the trial so far has been very encouraging, I get very excited. ;) I'm optimistic that we will understand whether or not kevetrin works by the end of phase I due to its design.

quote from your link:

In the drug discovery pipeline, Phase I trials are first used to evaluate if a new drug is safe, then Phase II trials are done to assess the drug’s efficacy, and finally Phase III trials are performed to monitor side effects and compare the drug to similar compounds already on the market. Each consecutive phase includes more people to refine the results obtained in the previous phase. A recent analysis by the Centre for Medicines Research in the UK has concluded that since 2008, the failure rate for drugs in Phase II and III clinical trials has been rising [1-2]. Phase II success rates are currently at 18%, lower than at any other phase of drug development.





In Reply to 'a1derfullife'
Pepsiman;

Actually, the 16.5% chance may be optimistic. See link.

Clinical Trial Failure Rates